CG Oncology (CGON) news
Recent news
CG Oncology Q2 revenue USD 1.157 million
CG Oncology, Inc. (NASDAQ: CGON) reported second-quarter 2025 revenue of $1.157 million , according to its financial results for the period ended June 30, 2025. This represents a significant decline from $640,000 in revenue recorded during the same period in 2024. The company’s revenue primarily…
AInvest Wire · Aug 6, 2026CG Oncology Q2 EPS USD -0.9
AInvest Wire · Aug 6, 2026CG Oncology Inc - files for offering of up to $500 mln common stock - SEC filing
AInvest Wire · Aug 6, 2026ANI Pharmaceuticals Inc: Continue to seek to recover value of assets it sold to CG Oncology in 2010
AInvest Wire · Jul 16, 2026Ani Pharmaceuticals - trial court denies Ani Pharmaceuticals' motion for new trial and judgment
On July 29, 2025, CG Oncology, Inc. (NASDAQ: CGON) announced a favorable verdict in its legal dispute with ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) following a jury trial in the Superior Court of the State of Delaware. The jury unanimously ruled in favor of CG Oncology on all claims brought by ANI…
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.